Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Drug

CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study

Fineline Cube Nov 11, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...

Company Drug

BeiGene’s Brukinsa Receives Marketing Approval in Brazil

Fineline Cube Nov 11, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has...

Company Drug

Fujian Cosunter Receives Multiple Patents for Cancer and Hepatitis Drugs

Fineline Cube Nov 11, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents...

Company Drug

Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study

Fineline Cube Nov 11, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...

Company Drug

3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...

Company Deals

Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab

Fineline Cube Nov 10, 2022

Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has...

Company Drug

LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China

Fineline Cube Nov 10, 2022

Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...

Company Deals

Innovex Medical Files for IPO in Hong Kong to Boost Product Development

Fineline Cube Nov 10, 2022

Innovex Medical Co., Ltd, a non-vascular interventional surgery solutions provider based in Shanghai, has filed...

Company Drug

NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma

Fineline Cube Nov 10, 2022

The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug,...

Company Drug

Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918

Fineline Cube Nov 10, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...

Policy / Regulatory

China Releases 14th Five-Year Plan for National Health Informatization

Fineline Cube Nov 10, 2022

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and the National Bureau...

Company

Zai Lab Reports 33% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q3 2022 earnings...

Company Deals

GSK Partners with CASPC to Advance HIV Sustained Care Advocacy in China

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline...

Company Drug

3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Boston Scientific Partners with Omron for Atrial Fibrillation Management

Fineline Cube Nov 10, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at...

Company Deals

Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda...

Company Drug

Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study

Fineline Cube Nov 10, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...

Company

BeiGene Reports 88% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) released its Q3 2022 earnings...

Company Deals

Shandong Xinhua and Bayer Announce Strategic Partnership at CIIE

Fineline Cube Nov 9, 2022

A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer...

Company Deals

Medtronic Partners with Shanghai JiaHui Hospital at CIIE

Fineline Cube Nov 9, 2022

US-based Medtronic Inc. (NYSE: MDT) has announced a partnership with Shanghai JiaHui International Hospital, unveiled...

Posts pagination

1 … 648 649 650 … 711

Recent updates

  • Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
  • WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.